

Efficacy of immunization against hepatitis B virus infection in acute leukemia

Akut lösemide hepatit B virüsü enfeksiyonuna karşı aşılama etkililiği

Tuphan Kanti Dolai, Manoranjan Mahapatra, Hara Prasad Pati, Pravas Mishra, Tulika Seth, Rahul Bhargava, Shyam Rathi, Niranjan Rathod, Renu Saxena

All India Institute of Medical Sciences (AIIMS), New Delhi, India

Abstract

Objective: The aim of this study was to assess the antibody response to combined passive-active immunization versus active immunization against hepatitis B in 71 patients with acute leukemia with negative hepatitis B virus serology at presentation.

Materials and Methods: The first group (n=28) received a double dose of hepatitis B vaccine at 0, 1, 2 and 6 months and immunoglobulin (HBIG) at 0 and 1 month concurrently with vaccine but at a different intramuscular site. The second group (n=43) received double dose of hepatitis B vaccine at 0, 1, 2, and 6 months. HBsAg and anti-HBs titers were determined one month after the 1st, 2nd, 3rd and 4th doses of vaccine.

Results: In the vaccine-only group, 2.56%, 8.33%, 14.28% and 34.29% of patients developed anti-HBs titer ≥ 10 IU/L after the 1st, 2nd, 3rd and 4th doses of vaccine, respectively. In the HBIG group, 91.30%, 91.30%, 69.56% and 73.91% of patients developed anti-HBs titer ≥ 10 IU/L after the 1st, 2nd, 3rd and 4th doses of vaccine, respectively. Those in the vaccine-HBIG group maintained their anti-HBs titer ≥ 10 IU/L from the 1st to the 4th doses. In the vaccine-only group, 34.29% of patients gained protective antibody titer after receiving the 4th dose of vaccine. Subgroup analysis of age (pediatric vs adult) and disease (acute lymphoblastic leukemia vs acute myeloid leukemia) groups showed no effect of either on the development of protective antibody titer. The incidence of HBsAg positivity one month after the 4th dose of vaccine was 8.62%. No patient became positive for anti-HCV or HIV antibody before or after chemo therapy.

Conclusion: Combined HBIG and vaccine may protect acute leukemia patients during the intensive chemotherapy period. (*Turk J Hematol 2010; 27: 156-61*)

Key words: Acute leukemia, hepatitis B vaccine, hepatitis B immunoglobulin

Received: May 27, 2009

Accepted: April 30, 2010

Özet

Amaç: Bu çalışmada, prezantasyonda negatif Hepatit B virüsü serolojisine sahip akut lösemili 71 hastada Hepatit B virüsüne karşı aktif aşılama karşısında birleşik pasif aktif aşılama yönelik antikor yanıtının değerlendirilmesi amaçlanmıştır.

Yöntem ve Gereçler: Birinci grup (n=28), 0. ay, 1. ay, 2. ay ve 6. ay zaman noktalarında ikili hepatit B aşısı dozu ve 0. ay, 1. ay zaman noktalarında aşı ile eşzamanlı olarak (ancak kas içi olarak) immüno-globulin (HBIG) almıştır. İkinci grup (n=43), 0. ay, 1. ay, 2. ay ve 6. ay zaman noktalarında ikili hepatit B aşısı dozu almıştır. HBsAg ve anti HBs titreleri, aşının 1. dozu, 2. dozu, 3. dozu ve 4. dozundan sonra yapılmıştır.

Bulgular: Yalnızca aşı yapılan grupta hastaların %2.56, %8.33, %14.28 ve %34.29'unda, sırasıyla 1., 2., 3. ve 4. aşı dozu verildikten sonra anti HBs titresi ≥ 10 IU/l oluşmuştur. HBIG grubunda, hastaların %91.30, %91.30, %69.56 ve %73.91'inde, sırasıyla 1., 2., 3. ve 4. aşı dozu verildikten sonra anti HBs titresi ≥ 10 IU/l oluşmuştur. HBIG alan hastalar, 1. dozdan 4. doza kadar ≥ 10 IU/l HBs titre değerini muhafaza etmiştir. Yalnızca aşı verilen grupta, hastaların %34.29'u 4. aşı dozu verildikten sonra koruyucu antikor titresi edinmiştir. Yaş (yetişkin karşısında pediatrik) ve hastalık (akut myeloid lösemi karşısında akut lenfoblastik lösemi) gruplarında, koruyucu antikor titresi gelişimi bakımında herhangi bir etki gözlenmemiştir. Aşının 4. dozundan bir ay sonar HBsAg pozitivite insidansı %8.62'dir. Kemoterapiden önce sonra, hiçbir hastada anti HCV ve HIV antikor için pozitivite gelişmemiştir.

Sonuç: Kombine HBIG ve aşı, yoğun kemoterapi periyodu sırasında akut lösemi hastalarını koruyabilir. (Turk J Hematol 2010; 27: 156-61)

Anahtar kelimeler: Akut lösemi, Hepatit B aşısı, Hepatit B immunoglobulin

Geliş tarihi: 27 Mayıs 2009

Kabul tarihi: 30 Nisan 2010

Introduction

Hepatitis B is one of the most important causes of acute and chronic hepatitis. Children with malignant disease are at an especially high risk for developing hepatitis B virus (HBV) infection from immunosuppression secondary to chemotherapy, radiotherapy and multiple blood transfusions. Most of the children infected with HBV develop chronic hepatitis. This plays an adverse prognostic role in terms of their disease-free survival because of delays in chemotherapy. The increasing potential for the cure of childhood malignant diseases emphasizes the need for a method of reducing hepatitis and its sequelae in these children.

Hepatitis B virus infection is prevalent in India. Among blood donors, pregnant women and the general population whose carrier frequency is 2%-4% and hepatitis B surface antibody (anti-HBs) positivity is around 18%-20% [1]. A high proportions of children treated for malignant disorders demonstrate seroconversion for HBV infection markers [2].

The high prevalence of HBV infection and relative failure of active immunization in patients with leukemia on therapy have prompted a search for alternative forms of prophylaxis [3]. Various studies have observed a decreased rate of transmission of the infection with passive immunization [4]. Thus, for protection against HBV infection, both active and passive immunization have been tried [5,6].

Since there are very few studies in this context, this study was undertaken to determine the efficacy of immunization (both active and passive) against HBV infection in acute leukemia patients.

Materials and Methods

The aims and objectives of this study were to determine the incidence of hepatitis B surface antigen (HBsAg) positivity before treatment, the efficacy of hepatitis B vaccine along with HBIG (hepatitis B immunoglobulin) in patients with acute leukemia, the anti-HBs titer level in the course of treatment and up to six months, and the HBsAg positivity rate in the course of treatment up to six months. A total of 114 patients with acute leukemia were tested for HBsAg and anti-HBs titer before starting treatment. Of the 114 patients, 3 were positive for HBsAg and 111 patients were negative for HBsAg. Out of 111 patients, 40 had anti-HBs titer ≥ 10 IU/L and 71 patients had anti-HBs titer < 10 IU/L. Thus, 71 patients were included in this study. This project was approved by the All India Institute of Medical Sciences (AIIMS) Ethics Committee. It is a prospective comparative trial including patients with acute leukemia with HBsAg, anti-HBs negativity before treatment and with anti-HBs titer < 10 IU/L. Those patients already immunized and with protective anti-HBs titer ≥ 10 IU/L were excluded from the study. Those who already completed immunization against hepatitis B and with anti-HBs titer < 10 IU/L were also included in this study. Immunization was started from induction. The first group (n=28) received hepatitis B vaccine (Engerix B - GlaxoSmithKline Biologicals, double dose, i.e. ≤ 11 years 20 mcg and > 11 years 40 mcg) at 0, 1, 2, and 6 months and HBIG (Hepabig- VHB Life Sciences Limited, Mumbai, India at a dose of 40 IU/kg maximum of 800 IU) at 0 and 1 month concurrently with

Engerix B but at a different intramuscular site. The second group (n=43) received only hepatitis B vaccine (Engerix B - double dose, i.e. ≤11 years 20 mcg and >11 years 40 mcg) at 0, 1, 2, and 6 months.

HBsAg and anti-HBs titer were determined one month after the 1st, 2nd, 3rd and 4th doses of vaccine. In those patients who were given Engerix B and HBIG and became HBsAg positive after starting treatment, subsequent doses of Engerix B and HBIG were not given. Anti-hepatitis C virus (HCV) total and human immunodeficiency virus (HIV) antibody were also tested before starting treatment and one month after the 4th dose of vaccine. HbsAg was tested using Hepanostika® HBsAg Ultra (bioMerieux bv Boseind 15, 5281RM Boxtel, The Netherlands). Anti-HBs was tested using VIDAS® (bioMérieux® sa, France).

Fisher's exact test and chi-square test were used to compare proportions between the groups. McNemar test was used to compare proportions within the group. Wilcoxon rank-sum (Mann-Whitney U) test was used to compare the medians. Two-sample t test was used to compare the median between the groups in equal variances. The statistical tests were performed by using STATA 9.0 and SPSS software version 11.5 for Windows®.

Results

Of these 114 patients, 3 (3%) were positive for HBsAg and 111 patients (97%) were negative for HBsAg. Out of 111 patients, 40 (36%) had anti-HBs titer ≥10 IU/L and 71 (64%) had anti-HBs titer <10 IU/L. Of those patients with anti-HBs titer ≥10 IU/L, 7 (18%) patients had past history of jaundice, 13 (33%) had history of previous vaccination and 20 (49%) had no history of jaundice or previous vaccination. A significant statistical difference (p=0.04) was found between pediatric and adult patients in anti-HBs titer ≥10 IU/L and anti- HBs titer <10 IU/L groups. The majority of pediatric patients had anti-HBs titer ≥10 IU/L compared to adults before starting chemotherapy.

The median age was 22 years (range, 1-52); 49 (69.01%) were male and 22 (30.99%) were female (Table 1). The total number of pediatric (≤18 yrs) patients was 31 (43.66%) and of adult (>18 yrs) patients was 40 (56.34%). The total number of acute lymphoblastic leukemia (ALL) patients was 38 (53.52%) and of acute myeloid leukemia (AML)

Table 1. Baseline patient characteristics according to vaccine group

Parameters	HBIG-Vaccine n=28 Median (range)	Vaccine-only n=43 Median (range)	P value (Mann-Whitney test)
Age in years	18 (3-44)	25 (1-52)	0.20
DDTT days	10 (2-142)	14 (1-147)	0.42
BT units	2 (0-18)	3 (0-40)	0.87
S. Bilirubin mg/dl	0.8 (0.6-5.8)	0.8 (0.5-4.6)	1.00
AST U/dl	27 (12-451)	29 (10-127)	0.96
ALT U/dl	31.5 (10-169)	36 (11-295)	0.87
ALP U/dl	243 (129-552)	232 (96-1270)	0.71
S. Protein g/dl	6.35 (4-7.6)	6.8 (4-9.5)	0.02*
S. Albumin g/dl	3.55 (2.1-4.6)	3.9 (2.3-4.8)	0.02*
S. Globulin g/dl	2.75 (1.9-4.3)	2.9 (1.7-5.1)	0.21*
Sex M/F	22 (44.9)/ 6 (39.44)	27 (55.10)/ 16 (72.73)	0.12 #
ALL/AML	20 (52.63)/ 8 (24.24)	18 (47.37)/ 25 (75.76)	0.01#
Age ≤18 yrs/ >18 yrs	20 (71.42)/ 8 (28.58)	11 (25.58)/ 32 (74.42)	0.0002#

HBIG: Hepatitis B immunoglobulin; DDTT: Duration of diagnosis to received treatment; BT: Blood transfusion; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase

*done by two sample t test; #done by Fisher's exact test

patients was 33 (46.48%). Nine patients (12.67%) died due to their disease and chemotherapy complications before the 2nd dose of vaccine; thus, 62 patients received a 2nd vaccine dose. Three patients died before receiving their 3rd dose of vaccine; thus, 59 patients received a 3rd vaccine dose. One patient died before receiving their 4th dose of vaccine; thus, 58 patients received a 4th vaccine dose.

In the vaccine-only group, 2.56%, 8.33%, 14.28% and 34.29% patients developed anti- HBs titer ≥10 IU/L after the 1st, 2nd, 3rd and 4th doses of vaccine, respectively. In the HBIG-vaccine group, 91.30%, 91.30%, 69.56% and 73.91% patients developed anti-HBs titer ≥10 IU/L after the 1st, 2nd, 3rd and 4th doses of vaccine, respectively, and 8.69%, 8.69%, 30.43% and 26.09% patients had anti-HBs titer <10 IU/L after the 1st, 2nd, 3rd and 4th doses of vaccine, respectively. Significantly statistical differences (Table 2) in anti-HBs titer (≥10 U/L) were seen between the two vaccine groups after the 1st, 2nd, 3rd and 4th doses of vaccine. Those who received HBIG maintained their anti-HBs titer ≥10 IU/L even one month after the 4th dose of vaccine. In the vac-

Table 2. Anti-HBs titer according to vaccine group at the different time points

Parameters	<10 IU/L,	≥10 IU/L	P value (Fisher's exact test)
One month after 1 st dose			
HBIG-Vaccine n=23, no (%)	2 (8.69)	21 (91.30)	0.0001
Vaccine-only n=39, no (%)	38 (97.43)	1 (2.56)	
One month after 2 nd dose			
HBIG-Vaccine n=23, no (%)	2 (8.69)	21 (91.30)	0.0001
Vaccine-only n=36, no (%)	33 (91.66)	3 (8.33)	
One month after 3 rd dose			
HBIG-Vaccine n=23, no (%)	7(30.43)	16 (69.56)	0.0001
Vaccine-only n=35, no (%)	30 (85.71)	5 (14.28)	
One month after 4 th dose			
HBIG-Vaccine n=23, no (%)	6 (26.09)	17 (73.91)	0.003
Vaccine-only n=35, no (%)	23 (65.71)	12 (34.29)	

HBIG: Hepatitis B immunoglobulin

cine-only group, after the 4th dose, anti-HBs titer ≥10 IU/L was achieved in 34.29% of patients, which was a very small proportion compared to the HBIG group. In both groups, a subgroup analysis was done between the ALL vs AML groups and pediatric vs adult groups. No significant differences were found between the ALL vs AML groups or between the pediatric vs adult groups.

In the pediatric age group, 72.72%, 58.33%, 47.61% and 41.37% patients developed anti-HBs titer ≥10 IU/L after the 1st, 2nd, 3rd and 4th doses of vaccine, respectively, whereas in the adult age group, 27.28%, 41.67%, 52.38% and 58.63% patients developed anti-HBs titer ≥10 IU/L after the 1st, 2nd, 3rd and 4th doses of vaccine, respectively. This showed that pediatric patients lost their anti-HBs titer gradually from the 1st to the 4th dose of vaccine. On the other hand, an increasing number of adult patients gained anti-HBs titer ≥10 IU/L gradually from the 1st to the 4th dose of vaccine. Statistical differences in anti-HBs titer ≥10 IU/L were seen between the two age

groups after the 1st (p=0.002) and 2nd (p=0.01) dose of vaccine, but not after the 3rd (p=0.40) and 4th (p=1.00) dose of vaccine. Thus, more pediatric patients developed anti-HBs titer ≥10 IU/L after the 1st and 2nd doses of vaccine compared to adult patients. Though more adult patients gained protective anti-HBs titer gradually from the 3rd to 4th doses of vaccine, when compared to the pediatric age group, the difference was statistically insignificant.

In the ALL group, 81.81%, 70.84%, 47.62% and 55.17% patients developed anti-HBs titer ≥10 IU/L after the 1st, 2nd, 3rd and 4th doses of vaccine, respectively, whereas in the AML group, 18.19%, 29.16%, 52.38% and 44.83% patients developed anti-HBs titer ≥10 IU/L after the 1st dose, 2nd, 3rd and 4th doses of vaccine, respectively. After the 1st dose of vaccine, a statistical difference in anti-HBs titer ≥10 IU/L was seen between the ALL and AML groups. No statistically significant differences were found after administration of the other doses (p values: 0.06 after 2nd dose, 0.28 after 3rd dose and 1.00 after 4th dose). A significant number of ALL patients developed protective antibody titer after the 1st vaccine dose compared to AML patients; thereafter, both groups behaved similarly.

One month after the 4th dose of vaccine, out of 58 patients, 5 patients (8.6%) were found HBsAg-positive. Among the HBsAg-positive patients, 1 (4.34%) was in the HBIG group and the remaining 4 (11.42%) were in the vaccine-only group. Of the HBsAg-positive patients, 3 had ALL and 2 had AML. No significant difference (p=0.63) in HBsAg positivity was found between the vaccine groups. After 210 days of follow up, none of the patients was found to be positive for anti-HCV or HIV antibody.

Discussion

A study from India showed that 47.8% of ALL patients were positive for HBsAg after therapy. In order to reduce the impact of HBV infection, schedules for active immunization, double doses of active immunization and both active and passive immunization against this infection have been investigated.

The HBsAg positivity rate (3%) in our study is quite similar to that of other studies performed in the general population in India. But the anti-HBs positivity rate in our study is quite high (40%) compared to other studies (18-20%) performed from India. This is probably due to the increased awareness of hepatitis B vaccination in the general popu-

lation. The HBsAg positivity rate of acute leukemia in this study was slightly high (3%) compared to that of an older study (1.85%) in ALL done by Marwaha et al. [2] from Chandigarh, India. It is probably due to the less sensitive method used for detection of HBsAg in 2001. Anti-HBs titer ≥ 10 IU/L was seen in more pediatric patients compared to adults, due to the increased awareness of hepatitis B vaccination in the pediatric population.

Goyal et al. [3] showed that after administration of double-dose vaccine during induction, consolidation and maintenance (0-1-2-12 months) chemotherapy, 19.7% patients developed anti-HBs titers and anti-HBs titer ≥ 10 IU/L was achieved in only 10.5% of patients. They detected HBsAg in 48.79% of their patients during the course of treatment. Another study from India by Somjee et al. [7] showed that at the end of six doses of vaccine (0-1-2-3-4-12), 29.75% of patients developed anti-HBs titers, and of them, only 18.9% had anti-HBs titer ≥ 10 IU/L. In the course of treatment, 43% of patients developed HBsAg positivity. A similar dose schedule as in our study (0-1-2-6) was tried in adult patients with acute leukemia (ALL & AML) by Gurina et al. [8]. In 30 patients, the rate of antibody positivity was 50% after the 4th dose of vaccine and 6.7% became infected with HBV over the three-year follow-up. A more intensive vaccination schedule (0-1-2-6-12) was used by Yetgin et al. [9] in 82 patients with childhood ALL. They found that the rate of antibody positivity was 35.4% after the 5th dose of vaccine, and 4.8% became infected with HBV after the end of vaccination. Our results are quite similar with the Yetgin et al. trial. An exact comparison with other studies is not possible because different vaccination schedules were used. In our study, more patients (34.29%) developed protective antibody titer after receiving their 4th dose of vaccine compared with other trials done by Goyal et al. [3] and Somjee et al. [7]. This is possibly due to the more severe immunosuppressive chemotherapy schedule used in their study. In our study, after a seven-month follow-up period, a small number (11.42%) of patients developed HBsAg positivity compared with other trials done by Goyal et al. and Somjee et al. This is due to improved infection control measures, safer blood supply in our hospital and the short duration of follow-up in our study. In spite of active immunization with recombinant DNA vaccine, some patients became infected with HBV infection. Thus, active immunization with recombinant DNA vaccine has a minimal role in these

immunosuppressed patients while they are on aggressive therapy.

A total of 28 patients received both vaccine and HBIG. Passively transferred immunity generated high titers of antibodies in these patients in the first 3 months. However, once these were eliminated over a period of another 3 months, active immunization was unable to confer sustained protection at 7 months. Therefore, it should be stressed that passive prophylaxis alone needs to be administered during the entire course of aggressive chemotherapy. Kavakli et al. [4] studied 22 patients with leukemia who received HBIG (800 IU once per month for 3 doses), together with vaccine at a different intramuscular site. HBV infection was not observed in any of the patients at the 4th and 12th months of serological follow-up. At the end of the first year, the antibody response reached 85%. In another study by Meral et al. [6], passive immunization with immunoglobulin (monthly for four doses) was given at the time of aggressive chemotherapy, and subsequently these patients were actively immunized with vaccine (40 mcg, 1-2-12 months) from the third month of maintenance therapy. Their rate of anti-HBs positivity was 90.3% at the end of the four doses, and at the end of the three-year follow-up, only 5 patients (16%) lost the protective antibody titers. In another Indian study by Somjee et al. [5], five doses of hepatitis B vaccine (ENGERIX-SmithKline Beecham) along with HBIG (HEPABIG-VHB Pharmaceuticals) were given in 31 ALL patients. Their rates of anti-HBs positivity were 89.6% at the end of 6 months, and at the end of 9 months, only 8 (42%) patients had lost the protective antibody titer. The rate of HBV infection was 27% at the end of 9 months. In our study, 73.91% of patients had developed anti-HBs titer ≥ 10 IU/L 1 month after the 4th dose of vaccine. This is a slightly inferior response compared to results of the Kavakli et al. [4], Meral et al. [6] and Somjee et al. [7] trials. The inferior response is possibly due to lesser doses of HBIG used in our trial (i.e. 2 doses of HBIG in our trial, 3 doses in Kavakli et al. trial, 4 doses in Meral et al. trial and 5 doses in Somjee et al. trial). Thus, a comparison of our study and other studies clearly shows that more doses of HBIG are required to achieve the maximum protective anti-HBs titers. Apart from that, HBIG may protect patients during the intensive chemotherapy period, but there must be sufficient antibody level during the entire period to decrease the rate of HBV infection in these patients. HBIG

could be given during aggressive treatment where maximum immunosuppression exists in addition to increased chances of exposure. This could be used in combination with more doses of active immunization, which may result in higher rates of antibody response.

In normal individuals, the rate of seroconversion following hepatitis B vaccine is almost 96%, and protective antibody levels can be achieved in 93% [3]. In the present study, despite the use of a double dose of vaccine and a more intensified vaccination program, seroconversion could be achieved in only 34.29% and 73.91% of the patients in the vaccine-only and vaccine-HBIG groups, respectively. This is because immunosuppression in leukemic patients resulting from the disease as well as the use of steroids lead to diminished response to initial or booster vaccination. Therefore, passive immunization with hyperimmunoglobulin followed by active immunization starting during maintenance therapy or after cessation of intensive chemotherapy may be a better alternative to achieve permanent protective antibody titers.

In the HBIG group, subgroup analysis was done between the ALL vs AML and pediatric vs adult groups. No statistically significant differences were found between the ALL vs AML groups or between the pediatric vs adult groups. Thus, differences in age and disease were not responsible for development of protective antibody titer. HBsAg positivity rate was similar between the two vaccine groups in the short follow-up period (7 months). The outcome of long-term follow-up might be different in terms of HBsAg positivity. Thus, long-term follow-up will be required to determine the efficacy of vaccination and the HBsAg positivity rate.

In conclusion, HBIG may protect patients during the intensive chemotherapy period, but there must be sufficient antibody level during the entire period to decrease the rate of HBV infection in these patients. To increase the level of protective antibody

titers (≥ 10 IU/L), both active and passive immunization are required. A large prospective multicenter randomized controlled trial is needed to address this issue.

Conflict of interest

No author of this paper has a conflict of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included in this manuscript.

References

1. Acharya SK, Panda SK. Hepatitis E virus: epidemiology, diagnosis, pathology and prevention. *Trop Gastroenterol* 2006;27:63-8.
2. Marwaha R, Rawat D, Chawla Y. Seroprevalence of hepatitis B and C viral infections at diagnosis and during the course of treatment in childhood malignancies. *Med Pediatr Oncol* 2001;37:166.
3. Goyal S, Pai SK, Kelkar R, Advani SH. Hepatitis B vaccination in acute lymphoblastic leukemia. *Leuk Res* 1998;22:193-5.
4. Kavakli K, Cetingul N, Oztop S. Combined administration of hepatitis B vaccine and hepatitis B immunoglobulin in children with cancer. *Pediatr Hematol Oncol* 1996;13:295-8.
5. Somjee S, Pai S, Parikh P, Banavali S, Kelkar R, Advani S. Passive active prophylaxis against hepatitis B in children with acute lymphoblastic leukemia. *Leuk Res* 2002;26:989-92.
6. Meral A, Sevinir B, Gunay U. Efficacy of immunization against hepatitis B virus infection in children with cancer. *Med Pediatr Oncol* 2000;35:47-51.
7. Somjee S, Pai S, Kelkar R, Advani S. Hepatitis B vaccination in children with acute lymphoblastic leukemia: results of an intensified immunization schedule. *Leuk Res* 1999;23:365-7.
8. Gurina NM, Svedentsov EP, Shardakov VI, Cherepanova VV. Vaccine prophylaxis of viral hepatitis B in patients with acute leukemia. *Ter Arkh* 2008;80:27-9.
9. Yetgin S, Tavil B, Aytac S, Kuskonmaz B, Kanra G. Unexpected protection from infection by two booster hepatitis B virus vaccination in children with acute lymphoblastic leukemia. *Leuk Res* 2007;31:493-6.